Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
NCT ID: NCT00871689
Last Updated: 2017-12-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
2 participants
INTERVENTIONAL
2009-01-31
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase II trial is studying the side effects of giving combination chemotherapy together with total-body irradiation followed by interleukin-2 (IL-2, aldesleukin), and umbilical cord blood transplant and to see how well it works in treating patients with relapsed or refractory acute myeloid leukemia.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To determine the rate of neutrophil engraftment and grade III-IV acute graft-versus-host disease (GVHD) following a T cell depleted (TCD) umbilical cord blood (UCB) transplantation without post-transplant immunosuppression followed by administration of interleukin-2 (IL-2, aldesleukin) (every other day) days +3 to +13 to expand NK cells in vivo.
Secondary
* To evaluate the safety of this regimen as assessed by monitoring the rates of graft failure, acute GVHD, and transplant-related mortality (TRM).
* To perform quantitative, phenotypic, and functional assessments of the in vivo expanded UCB-derived NK cells on (day +72).
* To assess clinical disease response (leukemia clearance and complete remission) and survival duration in these patients.
* To evaluate the tolerability of aldesleukin in these patients.
* To evaluate the tolerance of IL-2
OUTLINE:
* Preparative regimen: Patients receive fludarabine phosphate intravenously (IV) over 1 hour on days -7 to -5 and cyclophosphamide IV on days -7 and -6. Patients undergo total-body irradiation twice daily on days -5 to -2.
* Transplantation: Patients undergo T-cell depleted umbilical cord blood (UCB) transplantation on day 0.
* IL-2 (Aldesleukin) therapy: Patients receive aldesleukin subcutaneously on days +3 6 doses every other day) and +60 (6 doses every other day).
Patients are followed periodically for up to 2 years after transplant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
UCBT With Post-Transplant IL-2
Patients receive cyclophosphamide, fludarabine phosphate, total-body irradiation, T cell depleted umbilical cord blood transplantation (UCBT), followed by interleukin-2 (IL-2, aldesleukin) every other day beginning day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
aldesleukin
IL-2 will be administered (9 million units; 5 million units if weight is less than 45 kg) every other day beginning on day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
cyclophosphamide
60 mg/kg over 1 hour intravenously (IV) on days -7 and -6.
fludarabine phosphate
25 mg/m\^2 intravenously (IV) over 1 hour on days -7 through -5.
umbilical cord blood transplantation
On day 0, transplantation will occur with double T-cell depleted (TCD) umbilical cord blood (UCB) units
total-body irradiation
administered on days -5 through -2; 330 cGy daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
aldesleukin
IL-2 will be administered (9 million units; 5 million units if weight is less than 45 kg) every other day beginning on day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
cyclophosphamide
60 mg/kg over 1 hour intravenously (IV) on days -7 and -6.
fludarabine phosphate
25 mg/m\^2 intravenously (IV) over 1 hour on days -7 through -5.
umbilical cord blood transplantation
On day 0, transplantation will occur with double T-cell depleted (TCD) umbilical cord blood (UCB) units
total-body irradiation
administered on days -5 through -2; 330 cGy daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary induction failure defined as no complete remission (CR) after two or three induction cycles (no blast limit).
* Relapsed acute myeloid leukemia (AML) with low disease burden
* For patients 19 through 45 years of age: must have less than 10% marrow blasts at time of enrollment for patients who did not receive re-induction or measured at least 28 days from the start of re-induction therapy. Patients who have relapsed more than 12 months following a prior hematopoietic cell transplant (HCT) and did not reach CR following one re-induction cycle but have less than 10% marrow blasts are eligible.
* For patients 0 through 18 years of age: must have less than 50% marrow blasts after no more than 3 induction attempts
* CR3 or greater. This will include CRp defined as CR without platelet recovery to 100,000/mcL.
* CR1 or CR2 with high risk features (therapy induced, prior myelodysplastic syndrome (MDS) or myeloproliferative disease (MPD), high risk cytogenetic or molecular phenotype) with no available alternate (sibling, URD or UCB) donors.
* Patients with prior central nervous system (CNS) involvement are eligible provided that it has been treated and is in remission. CNS therapy (chemotherapy or radiation) should continue as medically indicated during the protocol.
* Have acceptable organ function within 14 days of enrollment defined as:
* Renal: creatinine ≤ 2.0 mg/dL (adult patients) or calculated creatinine clearance \> 40 ml/min (pediatric patients)
* Hepatic: bilirubin, AST/ALT, ALP ≤ 5 x upper limit of normal
* Pulmonary function: DLCOcorr \> 50% of normal, (oxygen saturation \[\>92%\] can be used in child where PFT's cannot be obtained)
* Cardiac: left ventricular ejection fraction ≥ 45%
* Karnofsky score (adults) \> 70% or Lansky score \> 50% (pediatrics)
* Women of childbearing potential must agree to use adequate contraception (diaphragm, birth control pills, injections, intrauterine device \[IUD\], surgical sterilization, subcutaneous implants, or abstinence, etc.) for the duration of treatment.
* All patients will be questioned about prior exposure to antibody therapy (including OKT3, rituximab, trastuzumab, and gemtuzumab) without affect to eligibility. Patients with prior exposure will have a blood sample collected for human anti-mouse antibody (HAMA). For patients with no prior antibody therapy exposure, no further action will be taken.
* Not receiving prednisone or other immunosuppressive medications
* Voluntary written consent
Exclusion Criteria
* Evidence of HIV infection or known HIV positive serology
* Pregnant or breast feeding. The agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy.
* If ≤ 18 years old, prior myeloablative transplant within the last 6 months. If \> 18 years old prior myeloablative allotransplant or autologous transplant
* Extensive prior therapy including \> 12 months of any alkylator chemotherapy (etoposide \>100 mg/m\^2 x 5 days, cyclophosphamide \>1 gm/m\^2 or mitoxantrone \>8 gm/m\^2) delivered at 3-4 week intervals or \> 6 months alkylator therapy (as above) with extensive radiation (determined by Radiation Oncology, e.g. mantle irradiation for Hodgkin's) and/or prior radiation therapy that makes a patient ineligible for total body irradiation (TBI).
Criteria for Second Course of IL-2 (begin day +60):
* No Graft-Versus-Host Disease (GVHD), active infection or any other severe medical co-morbidity
* Absolute neutrophil count (ANC) \> 1000 without growth factor support
* No grade 4 toxicity (except fevers) attributed to IL-2 during course #1
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Masonic Cancer Center, University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael R. Verneris, MD
Role: PRINCIPAL_INVESTIGATOR
Masonic Cancer Center, University of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Minnesota Children's Hospital - Fairview
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MT2008-36
Identifier Type: OTHER
Identifier Source: secondary_id
0810M51781
Identifier Type: OTHER
Identifier Source: secondary_id
2008LS110
Identifier Type: -
Identifier Source: org_study_id